We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in the Cards for Merrimack (MACK) in Q3 Earnings?
Read MoreHide Full Article
Merrimack Pharmaceuticals, Inc. (MACK - Free Report) is expected to report third-quarter 2017 results around Nov 8, before market opens. Last quarter, Merrimack missed bottom-line expectations by 57.14%.
Merrimack’s share price has decreased 71.3% year to date against the industry’s gain of 3.9%.
Let’s see how things are shaping up for the company this quarter.
Factors to Consider
Merrimack sold its only marketed product Onivyde in April 2017 due to a disappointing launch and subsequent unimpressive sales. The company received $575 million in cash from its asset sale to Ipsen.
Merrimack is also eligible to receive up to $450 million in additional regulatory approval-based milestone payments as part of the deal.
The company reduced its outstanding debt and invested in the development of its oncology pipeline.
Merrimack is now focused on the development of three pipeline candidates – MM-121/seribantumab (heregulin-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC), MM-141/istiratumab (pancreatic cancer) and MM-310 (solid tumor).
MM-141 is currently being evaluated in a phase II study, CARRIE, for metastatic pancreatic cancer, which completed enrollment in June. The company expects to report data in the first half of 2018. Moreover, MM-121 is currently in a phase II study, SHERLOC in NSCLC patients with heregulin positive. Merrimack plans to initiate another phase II study, SHERBOC, to evaluate MM-121 in breast cancer.
Subsequent to the quarter in October, the FDA granted orphan drug designation to MM-121 for a lung cancer study.
The company may provide a preliminary update related to the studies on its earnings call.
Surprise History
Merrimack’s track record has been dismal so far with a four-quarter average negative earnings surprise of 65.44%. The company has missed estimates thrice in the four trailing quarters while beating the same only once.
Earnings Whispers
Our proven model does not conclusively show that Merrimack is likely to beat estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. But that is not the case here, as you will see below.
Zacks ESP: Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is 0.00%. This is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at a loss of $1.88. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Merrimack’s has Zacks Rank #4 (Sell).
Note that we caution against stocks with a Zacks Rank #4 or 5 (Strong Sell) going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Merrimack Pharmaceuticals, Inc. Price and EPS Surprise
Here are a couple of health care stocks that you may want to consider, as our model shows that it has the right combination of elements to post an earnings beat this quarter.
Cidara Therapeutics, Inc. (CDTX - Free Report) is scheduled to release results on Nov 8. The company has an Earnings ESP of +16.06% and a Zacks Rank #2.
Regenxbio Inc. (RGNX - Free Report) is scheduled to release results on Nov 8. The company has an Earnings ESP of +4.23% and a Zacks Rank #2.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
What's in the Cards for Merrimack (MACK) in Q3 Earnings?
Merrimack Pharmaceuticals, Inc. (MACK - Free Report) is expected to report third-quarter 2017 results around Nov 8, before market opens. Last quarter, Merrimack missed bottom-line expectations by 57.14%.
Merrimack’s share price has decreased 71.3% year to date against the industry’s gain of 3.9%.
Let’s see how things are shaping up for the company this quarter.
Factors to Consider
Merrimack sold its only marketed product Onivyde in April 2017 due to a disappointing launch and subsequent unimpressive sales. The company received $575 million in cash from its asset sale to Ipsen.
Merrimack is also eligible to receive up to $450 million in additional regulatory approval-based milestone payments as part of the deal.
The company reduced its outstanding debt and invested in the development of its oncology pipeline.
Merrimack is now focused on the development of three pipeline candidates – MM-121/seribantumab (heregulin-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC), MM-141/istiratumab (pancreatic cancer) and MM-310 (solid tumor).
MM-141 is currently being evaluated in a phase II study, CARRIE, for metastatic pancreatic cancer, which completed enrollment in June. The company expects to report data in the first half of 2018. Moreover, MM-121 is currently in a phase II study, SHERLOC in NSCLC patients with heregulin positive. Merrimack plans to initiate another phase II study, SHERBOC, to evaluate MM-121 in breast cancer.
Subsequent to the quarter in October, the FDA granted orphan drug designation to MM-121 for a lung cancer study.
The company may provide a preliminary update related to the studies on its earnings call.
Surprise History
Merrimack’s track record has been dismal so far with a four-quarter average negative earnings surprise of 65.44%. The company has missed estimates thrice in the four trailing quarters while beating the same only once.
Earnings Whispers
Our proven model does not conclusively show that Merrimack is likely to beat estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. But that is not the case here, as you will see below.
Zacks ESP: Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is 0.00%. This is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at a loss of $1.88. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Merrimack’s has Zacks Rank #4 (Sell).
Note that we caution against stocks with a Zacks Rank #4 or 5 (Strong Sell) going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Merrimack Pharmaceuticals, Inc. Price and EPS Surprise
Merrimack Pharmaceuticals, Inc. Price and EPS Surprise | Merrimack Pharmaceuticals, Inc. Quote
Stocks That Warrant a Look
Here are a couple of health care stocks that you may want to consider, as our model shows that it has the right combination of elements to post an earnings beat this quarter.
Agenus Inc. (AGEN - Free Report) is scheduled to release results on Nov 7 with an Earnings ESP of +8.11% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Cidara Therapeutics, Inc. (CDTX - Free Report) is scheduled to release results on Nov 8. The company has an Earnings ESP of +16.06% and a Zacks Rank #2.
Regenxbio Inc. (RGNX - Free Report) is scheduled to release results on Nov 8. The company has an Earnings ESP of +4.23% and a Zacks Rank #2.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>